Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd. ( (AU:RAC) ) has shared an update.
Racura Oncology Ltd, an Australian oncology-focused biotech company listed on the ASX under ticker RAC, has issued a new tranche of 146,524 ordinary fully paid shares. The move marginally increases the company’s listed equity base and reflects the conversion or exercise of existing securities, slightly diluting existing holdings while potentially supporting future funding flexibility and liquidity in its stock.
The newly issued shares are scheduled to be quoted on 9 April 2026, following the company’s formal application to the ASX for quotation. This technical capital markets step signals routine balance-sheet and capital-structure management rather than a strategic shift, but it may modestly enhance trading volumes and broaden the share register for investors in the oncology biotech space.
The most recent analyst rating on (AU:RAC) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology Ltd is an Australian-listed biotechnology company focused on oncology, with its ordinary fully paid shares traded on the ASX under the ticker RAC. The company operates in the cancer therapeutics sector, developing treatments aimed at improving clinical outcomes for patients and creating value for shareholders in the healthcare and life sciences market.
Average Trading Volume: 189,693
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$462.9M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.